Bulletin
Investor Alert

ICU Medical Inc.

NAS: ICUI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
ICU Medical Inc.

After Hours

 --Quotes are delayed by 20 min

Jun 9, 2023, 5:57 p.m.

ICUI
/zigman2/quotes/208026181/composite

$

185.85

Change

-2.95 -1.56%

Volume

Volume 2,290

Quotes are delayed by 20 min

/zigman2/quotes/208026181/composite

Previous close

$ 191.93

$ 188.80

Change

-3.13 -1.63%

Day low

Day high

$187.95

$192.57

Open

52 week low

52 week high

$128.90

$212.43

Open

Company Description

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems...

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Valuation

Price to Sales Ratio

1.65

Price to Book Ratio

1.81

Enterprise Value to EBITDA

25.06

Enterprise Value to Sales

2.65

Total Debt to Enterprise Value

0.33

Efficiency

Revenue/Employee

156,977.00

Income Per Employee

-5,123.00

Receivables Turnover

13.58

Total Asset Turnover

0.71

Liquidity

Current Ratio

2.49

Quick Ratio

1.09

Cash Ratio

0.43

Profitability

Gross Margin

29.11

Operating Margin

-0.67

Pretax Margin

-5.03

Net Margin

-3.26

Return on Assets

-2.32

Return on Equity

-4.01

Return on Total Capital

-0.55

Return on Invested Capital

-2.74

Capital Structure

Total Debt to Total Equity

83.02

Total Debt to Total Capital

45.36

Total Debt to Total Assets

38.42

Long-Term Debt to Equity

80.69

Long-Term Debt to Total Capital

44.09

Officers and Executives

Name Age Officer Since Title
Mr. Vivek Jain 47 2014 Chairman & Chief Executive Officer
Mr. Christian Voigtlander 51 2017 Vice President-Business Development
Mr. Brian M. Bonnell - 2018 Vice President-Finance
Mr. Krishna Uppugonduri - 2015 VP-Quality, Medical & Regulatory Affairs
Mr. Daniel Woolson 43 2017 Vice President & General Manager-Infusion Systems

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/11/2023 Virginia Sanzone
VP, General Counsel 		250   Disposition at $175 per share. 43,750
04/05/2023 Virginia Sanzone
VP, General Counsel 		458   Disposition at $170 per share. 77,860
03/08/2023 Vivek Jain
Chairman and CEO; Director 		1,329   Derivative/Non-derivative trans. at $156.17 per share. 207,549
03/08/2023 Christian B. Voigtlander
Chief Operating Officer 		1,163   Derivative/Non-derivative trans. at $156.17 per share. 181,625
03/08/2023 Brian M. Bonnell
Chief Financial Officer 		1,163   Derivative/Non-derivative trans. at $156.17 per share. 181,625
03/08/2023 Daniel Woolson
VP, GM-Infusion Capital 		894   Derivative/Non-derivative trans. at $156.17 per share. 139,615
03/08/2023 Virginia Sanzone
VP, General Counsel 		1,196   Derivative/Non-derivative trans. at $156.17 per share. 186,779
03/08/2023 Vivek Jain
Chairman and CEO; Director 		2,525   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2023 Christian B. Voigtlander
Chief Operating Officer 		2,209   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2023 Brian M. Bonnell
Chief Financial Officer 		2,209   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2023 Daniel Woolson
VP, GM-Infusion Capital 		2,020   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2023 Virginia Sanzone
VP, General Counsel 		2,272   Derivative/Non-derivative trans. at $0 per share. 0
03/07/2023 Vivek Jain
Chairman and CEO; Director 		1,694   Derivative/Non-derivative trans. at $157.47 per share. 266,754
03/07/2023 Christian B. Voigtlander
Chief Operating Officer 		1,129   Derivative/Non-derivative trans. at $157.47 per share. 177,783
03/07/2023 Brian M. Bonnell
Chief Financial Officer 		1,129   Derivative/Non-derivative trans. at $157.47 per share. 177,783
03/07/2023 Daniel Woolson
VP, GM-Infusion Capital 		428   Derivative/Non-derivative trans. at $157.47 per share. 67,397
03/07/2023 Virginia Sanzone
VP, General Counsel 		564   Derivative/Non-derivative trans. at $157.47 per share. 88,813
03/07/2023 Vivek Jain
Chairman and CEO; Director 		3,218   Derivative/Non-derivative trans. at $0 per share. 0
03/07/2023 Christian B. Voigtlander
Chief Operating Officer 		2,145   Derivative/Non-derivative trans. at $0 per share. 0
03/07/2023 Brian M. Bonnell
Chief Financial Officer 		2,145   Derivative/Non-derivative trans. at $0 per share. 0
03/07/2023 Daniel Woolson
VP, GM-Infusion Capital 		965   Derivative/Non-derivative trans. at $0 per share. 0
03/07/2023 Virginia Sanzone
VP, General Counsel 		1,072   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Vivek Jain
Chairman and CEO; Director 		5,261   Derivative/Non-derivative trans. at $161.25 per share. 848,336
03/06/2023 Vivek Jain
Chairman and CEO; Director 		933   Derivative/Non-derivative trans. at $161.25 per share. 150,446
03/06/2023 Christian B. Voigtlander
Chief Operating Officer 		816   Derivative/Non-derivative trans. at $161.25 per share. 131,580
03/06/2023 Christian B. Voigtlander
Chief Operating Officer 		4,604   Derivative/Non-derivative trans. at $161.25 per share. 742,395
03/06/2023 Brian M. Bonnell
Chief Financial Officer 		4,604   Derivative/Non-derivative trans. at $161.25 per share. 742,395
03/06/2023 Brian M. Bonnell
Chief Financial Officer 		816   Derivative/Non-derivative trans. at $161.25 per share. 131,580
03/06/2023 Daniel Woolson
VP, GM-Infusion Capital 		626   Derivative/Non-derivative trans. at $161.25 per share. 100,942
03/06/2023 Virginia Sanzone
VP, General Counsel 		839   Derivative/Non-derivative trans. at $161.25 per share. 135,288
03/06/2023 Vivek Jain
Chairman and CEO; Director 		9,994   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Vivek Jain
Chairman and CEO; Director 		1,773   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Christian B. Voigtlander
Chief Operating Officer 		1,551   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Christian B. Voigtlander
Chief Operating Officer 		8,745   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Brian M. Bonnell
Chief Financial Officer 		8,745   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Brian M. Bonnell
Chief Financial Officer 		1,551   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Daniel Woolson
VP, GM-Infusion Capital 		1,417   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2023 Virginia Sanzone
VP, General Counsel 		1,595   Derivative/Non-derivative trans. at $0 per share. 0
02/02/2023 Daniel Woolson
VP, GM-Infusion Capital 		1,731   Disposition at $200 per share. 346,200
11/15/2022 Virginia Sanzone
VP, General Counsel 		325   Disposition at $160.12 per share. 52,039
09/21/2022 George A. Lopez
Director 		79,576   Derivative/Non-derivative trans. at $61.76 per share. 4,914,613
05/23/2022 Vivek Jain
Chairman and CEO; Director 		30   Gift at $0 per share. 0
05/13/2022 Elisha Wade Finney
Director 		743   Gift at $0 per share. 0
/news/latest/company/us/icui

MarketWatch News on ICUI

  1. Edwards Lifesciences Corp. stock rises Friday, outperforms market

    5:45 p.m. Nov. 25, 2022

    - MarketWatch Automation

  3. Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market

    5:53 p.m. Nov. 22, 2022

    - MarketWatch Automation

  5. Edwards Lifesciences Corp. stock rises Friday, outperforms market

    5:52 p.m. Nov. 18, 2022

    - MarketWatch Automation

  6. Edwards Lifesciences Corp. stock falls Thursday, underperforms market

    5:53 p.m. Nov. 17, 2022

    - MarketWatch Automation

  7. Edwards Lifesciences Corp. stock falls Wednesday, underperforms market

    5:53 p.m. Nov. 16, 2022

    - MarketWatch Automation

  8. Edwards Lifesciences Corp. stock rises Tuesday, outperforms market

    5:53 p.m. Nov. 15, 2022

    - MarketWatch Automation

  10. ICU Medical downgraded to market perform from outperform at Raymond James

    12:07 p.m. Nov. 8, 2022

    - Tomi Kilgore

  11. Edwards Lifesciences Corp. stock falls Friday, still outperforms market

    5:52 p.m. Feb. 11, 2022

    - MarketWatch Automation

  12. Edwards Lifesciences Corp. stock falls Thursday, still outperforms market

    5:52 p.m. Feb. 10, 2022

    - MarketWatch Automation

  14. Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market

    5:52 p.m. Feb. 8, 2022

    - MarketWatch Automation

  15. Edwards Lifesciences Corp. stock falls Monday, underperforms market

    5:52 p.m. Feb. 7, 2022

    - MarketWatch Automation

  16. Edwards Lifesciences Corp. stock rises Friday, outperforms market

    5:52 p.m. Feb. 4, 2022

    - MarketWatch Automation

  18. Edwards Lifesciences Corp. stock rises Wednesday, outperforms market

    5:53 p.m. Feb. 2, 2022

    - MarketWatch Automation

  19. Edwards Lifesciences Corp. stock falls Tuesday, underperforms market

    5:53 p.m. Feb. 1, 2022

    - MarketWatch Automation

  20. Edwards Lifesciences Corp. stock rises Monday, outperforms market

    5:52 p.m. Jan. 31, 2022

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/icui

Other News on ICUI

  1. 10-K: ICU MEDICAL INC/DE

    6:34 p.m. Feb. 27, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. ICU Medical, Inc. (ICUI) Q3 2022 Earnings Call Transcript

    1:42 a.m. Nov. 8, 2022

    - Seeking Alpha

  4. 10-Q: ICU MEDICAL INC/DE

    6:31 p.m. Nov. 7, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. New Strong Sell Stocks for September 8th

    6:08 a.m. Sept. 8, 2022

    - Zacks.com

  7. New Strong Sell Stocks for August 11th

    6:27 a.m. Aug. 11, 2022

    - Zacks.com

  8. 10-Q: ICU MEDICAL INC/DE

    6:11 a.m. Aug. 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

At a Glance

ICU Medical, Inc.

951 Calle Amanecer

San Clemente, California 92673-6212

Phone

1 9493662183

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$2.28B

Net Income

$-74.29M

2022 Sales Growth

72.9%

Employees

14,500

Annual Report for ICUI

/news/pressrelease/company/us/icui

Press Releases on ICUI

  1. ICU Medical Announces First Quarter 2023 Results

    4:06 p.m. May 8, 2023

    - GlobeNewswire

  9. ICU Medical Announces Third Quarter 2022 Results

    5:06 p.m. Nov. 7, 2022

    - GlobeNewswire

  12. ICU Medical Announces Second Quarter 2022 Results

    4:06 p.m. Aug. 8, 2022

    - GlobeNewswire

Link to MarketWatch's Slice.